# PAXIPEM (NCT05096390)

> Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05096390
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Centre Leon Berard
- Conditions: Papillary Renal Cell Carcinoma Type 2
- Interventions: Axitinib Oral Tablet [Inlyta]; Pembrolizumab Injection [Keytruda]
- Enrollment: 72
- Primary outcome: Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.

## Commentary we found

- YouTube: 3
- X threads: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=paxipem-nct05096390

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05096390", "email": "<work email>"}; the inbox owner confirms by the emailed link.